{"entity":{"id":"hopec-pharma","kind":"company","name":"Hopec Pharma","aka":["HOPEC Pharma","Hopec-Pharma"],"tldr":"Hopec Pharma is an Israeli company developing an immune treatment for early bladder cancer made from an inactivated, genetically modified E. coli bacterium. It is in a first trial in people whose cancer came back after BCG or chemotherapy in the bladder.","summary":"Hopec Pharma, of Givat Shmuel, Israel, develops Inactivated UPEC-FimON, an immunotherapy based on a genetically modified uropathogenic Escherichia coli for non-muscle invasive bladder cancer; Estee Rosen is co-founder and chief executive. The company describes partnerships with the Hebrew University, Hadassah and Sheba. Its first registered cancer trial, NCT07881666, an open-label multicentre phase 1 study of intravesical inactivated UPEC-FimON in non-muscle invasive urothelial carcinoma after failure of BCG or intravesical chemotherapy, at Kfar Saba, Jerusalem and Ramat Gan, was posted on ClinicalTrials.gov in October 2026; the registry gives its start as October 2025.","asOf":"2026-10-29","links":[{"label":"Official website","url":"https://www.hopec-pharma.com/"},{"label":"About Hopec Pharma","url":"https://www.hopec-pharma.com/about"},{"label":"ClinicalTrials.gov: phase 1 trial of UPEC-FimON (NCT07881666)","url":"https://clinicaltrials.gov/study/NCT07881666"}],"tags":[],"related":[],"cancers":["non-muscle-invasive-bladder-cancer"],"sections":["immunotherapy"],"technologies":["bcg-and-intravesical-therapy"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["The company website calls the product a 'non-intravesical immunotherapy', while the registry record describes intravesical administration; the registry is followed here. Founding year and financing not stated on the pages read. Read on 29 October 2026."],"hq":"Givat Shmuel","country":"IL","companyType":"biotech","website":"https://www.hopec-pharma.com/","stage":"startup","investors":[],"funding":[]},"route":"/companies/hopec-pharma/","neighbours":{"cancer":[{"id":"non-muscle-invasive-bladder-cancer","kind":"cancer","name":"Non-muscle-invasive bladder cancer","route":"/cancers/non-muscle-invasive-bladder-cancer/"}],"section":[{"id":"immunotherapy","kind":"section","name":"Immunotherapy","route":"/fronts/immunotherapy/"}],"technology":[{"id":"bcg-and-intravesical-therapy","kind":"technology","name":"Intravesical therapy (BCG, chemotherapy, devices, gene and viral therapy)","route":"/technologies/bcg-and-intravesical-therapy/"}]}}